FDA Priority Review for Verastem's duvelisib

Verastem Inc. (NASDAQ:VSTM) said FDA accepted and granted Priority Review

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE